Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes

被引:95
作者
Bondanza, A
Valtolina, V
Magnani, Z
Ponzoni, M
Fleischhauer, K
Bonyhadi, M
Traversari, C
Sanvito, F
Toma, S
Radrizzani, M
La Seta-Catamancio, S
Ciceri, F
Bordignon, C
Bonini, C
机构
[1] Univ Vita Salute San Raffaele, Canc Immunotherapy & Gene Therapy Program, Expt Hematol Lab,S Raffaele Sci Inst, DIBIT3A1, I-20132 Milan, Italy
[2] Molmed SpA, Milan, Italy
[3] Xcyte Therapies, Seattle, WA USA
关键词
D O I
10.1182/blood-2005-09-3716
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In allogeneic hematopoietic cell transplantation (allo-HCT), the immune recognition of host antigens by donor T lymphocytes leads to a beneficial graft-versus-leukemia (GvL) effect as well as to life-threatening graft-versus-host disease (GvHD). Genetic modification of T lymphocytes with a retroviral vector (RV) expressing the herpes simplex virus-thymidine kinase (TK) suicide gene confers selective sensitivity to the prodrug ganciclovir (GCV). In patients, the infusion of TK+ lymphocytes and the subsequent administration of GCV resulted in a time-wise modulation of antihost reactivity for a GvL effect, while controlling GvHD. Because activation required for genetic modification with RV may reduce antihost reactivity, we investigated the requirements for maximizing the potency of human TK+ lymphocytes. Whereas T-cell receptor triggering alone led to effector memory (EM) TK+ lymphocytes, the addition of CD28 costimulation through cell-sized beads resulted in the generation of central memory (CM) TK+ lymphocytes. In a quantitative model for GvHD using nonobese diabetic/severely combined immunodeficient mice, CM TK+ lymphocytes were more potent than EM TK+ lymphocytes. GCV administration efficiently controlled GvHD induced by CM TK+ lymphocytes. These results warrant the clinical investigation of CM suicide gene-modified human T lymphocytes for safe and effective allo-HCT.
引用
收藏
页码:1828 / 1836
页数:9
相关论文
共 57 条
[1]   Memory CD4+ T cells do not induce graft-versus-host disease [J].
Anderson, BE ;
McNiff, J ;
Yan, J ;
Doyle, H ;
Mamula, M ;
Shlomchik, MJ ;
Shlomchik, WD .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (01) :101-108
[2]   Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation:: a phase 1/2 study [J].
André-Schmutz, I ;
Le Deist, F ;
Hacein-Bey-Abina, S ;
Vitetta, E ;
Schindler, J ;
Chedeville, G ;
Vilmer, E ;
Fischer, A ;
Cavazzana-Calvo, M .
LANCET, 2002, 360 (9327) :130-137
[3]   Haematopoietic cell transplantation as immunotherapy [J].
Appelbaum, FR .
NATURE, 2001, 411 (6835) :385-389
[4]   CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy [J].
Berger, C ;
Blau, CA ;
Clackson, T ;
Riddell, SR ;
Heimfeld, S .
BLOOD, 2003, 101 (02) :476-484
[5]   Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes [J].
Berney, T ;
Molano, RD ;
Pileggi, A ;
Cattan, P ;
Li, H ;
Ricordi, C ;
Inverardi, L .
TRANSPLANTATION, 2001, 72 (01) :133-140
[6]  
Bondanza A, 2005, METH MOLEC MED, V109, P475
[7]   Safety of retroviral gene marking with a truncated NGF receptor [J].
Bonini, C ;
Grez, M ;
Traversari, C ;
Ciceri, F ;
Marktel, S ;
Ferrari, G ;
Dinauer, M ;
Sadat, M ;
Aiuti, A ;
Deola, S ;
Radrizzani, M ;
Hagenbeek, A ;
Apperley, J ;
Ebeling, S ;
Martens, A ;
Kolb, HJ ;
Weber, M ;
Lotti, F ;
Grande, A ;
Weissinger, E ;
Bueren, JA ;
Lamana, M ;
Falkenburg, JHF ;
Heemskerk, MHM ;
Austin, T ;
Kornblau, S ;
Marini, F ;
Benati, C ;
Magnani, Z ;
Cazzaniga, S ;
Toma, S ;
Gallo-Stampino, C ;
Introna, M ;
Slavin, S ;
Greenberg, PD ;
Bregni, M ;
Mavilio, F ;
Bordignon, C .
NATURE MEDICINE, 2003, 9 (04) :367-369
[8]   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].
Bonini, C ;
Ferrari, G ;
Verzeletti, S ;
Servida, P ;
Zappone, E ;
Ruggieri, L ;
Ponzoni, M ;
Rossini, S ;
Mavilio, F ;
Traversari, C ;
Bordignon, C .
SCIENCE, 1997, 276 (5319) :1719-1724
[9]   Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].
Brentjens, RJ ;
Latouche, JB ;
Santos, E ;
Marti, F ;
Gong, MC ;
Lyddane, C ;
King, PD ;
Larson, S ;
Weiss, M ;
Rivière, I ;
Sadelain, M .
NATURE MEDICINE, 2003, 9 (03) :279-286
[10]   Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence [J].
Cavalieri, S ;
Cazzaniga, S ;
Geuna, M ;
Magnani, Z ;
Bordignon, C ;
Naldini, L ;
Bonini, C .
BLOOD, 2003, 102 (02) :497-505